Ticker
ADMP

Price
0.34
Stock movement up
+0.00 (0.50%)
Company name
Adamis Pharma
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-Specialty & Generic
Market cap
50.87M
Ent value
47.76M
Price/Sales
4.79
Price/Book
3.20
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-69.44%
3 year return
-29.62%
5 year return
-42.18%
10 year return
-27.99%
Last updated: 2022-08-25

DIVIDENDS

ADMP does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.79
Price to Book3.20
EV to Sales4.50

FINANCIALS

Per share

Loading...
Per share data
Current share count149.98M
EPS (TTM)-0.12
FCF per share (TTM)-0.24

Income statement

Loading...
Income statement data
Revenue (TTM)10.62M
Gross profit (TTM)903.48K
Operating income (TTM)-34.29M
Net income (TTM)-17.79M
EPS (TTM)-0.12
EPS (1y forward)-0.05

Margins

Loading...
Margins data
Gross margin (TTM)8.51%
Operating margin (TTM)-322.78%
Profit margin (TTM)-167.50%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash17.77M
Net receivables4.60M
Total current assets27.79M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets30.55M
Accounts payable4.89M
Short/Current long term debt2.46M
Total current liabilities13.58M
Total liabilities14.65M
Shareholder's equity15.90M
Net tangible assets15.90M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-47.28M
Capital expenditures (TTM)1.11M
Free cash flow (TTM)-36.08M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-111.90%
Return on Assets-58.24%
Return on Invested Capital-109.45%
Cash Return on Invested Capital-221.94%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.34
Daily high0.34
Daily low0.33
Daily Volume249K
All-time high1835.63
1y analyst estimate0.42
Beta1.19
EPS (TTM)-0.12
Dividend per share-
Ex-div date-
Next earnings date21 Nov 2022

Downside potential

Loading...
Downside potential data
ADMPS&P500
Current price drop from All-time high-99.98%-12.18%
Highest price drop-99.98%-56.47%
Date of highest drop22 Aug 20229 Mar 2009
Avg drop from high-79.93%-11.38%
Avg time to new high247 days12 days
Max time to new high5606 days1805 days
COMPANY DETAILS
ADMP (Adamis Pharma) company logo
Marketcap
50.87M
Marketcap category
Small-cap
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Employees
15
Investor relations
-
SEC filings
CEO
Dennis J. Carlo
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infe...
September 21, 2022
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo Indep...
September 21, 2022
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO, Sept...
September 12, 2022
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announce...
August 12, 2022
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ETSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopha...
August 10, 2022
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
August 8, 2022
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on Aug...
July 29, 2022
Interim DSMB review expected in late SeptemberSAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phas...
July 29, 2022
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdo...
July 21, 2022
Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
May 31, 2022
Next page